A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate the efficacy and the safety of YH14642 in Korea patients with chronic periodontitis, in order to investigate the recommended therapeutic dose.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yuhan Corporation
• Treatments: Doxycycline

Criteria

Inclusion Criteria:

• Subjects must be 20 years of age or older

• Have at least 18 natural teeth

• Four or more clinical attachment level(CAL) ≥ 3mm

• Four or more periodontal pockets with a probing depth (PD) ≥ 4mm

• Have Bleeding on probing

• Provide informed consent and willingness to cooperate with the study protocol

Exclusion Criteria:

• Forbidden History of Panax Notoginseng and Rehmanniae Radix Preparata

• Hypersensitivity of Doxycycline

• Hypersensitivity of Zea mays L. extract

• Critical diseases such as HIV previous three years

• Patients with mental retardation and dementia

• Systemic diseases such as diabetes and hypertension

• Patients who take Anticoagulants or Antiplatelet Agents

• Patients who have malignant tumor

• Smoker

• Continually use for 2weeks of phenytoin, calcium channel blocker, cyclosporin, coumarin, nonsteroidal anti-inflammatory drugs and aspirin use in the previous one month

• Patients who need malignant tumor

• Patients who received periodontal treatment within the last 6 months

• Pregnant or lactating females